Talphera (TLPH) Research & Development (2010 - 2026)
Talphera (TLPH) posted Research & Development of $1.7 million for Q2 2026, up 2.42% on a QoQ basis from $1.6 million in Q1 2026, and up 12.67% year-over-year from $1.5 million in Q2 2025.
Analysis
Talphera (TLPH) Research & Development (2010 - 2026) Analysis & Trends
Talphera has reported Research & Development for 17 years, with the latest figure at $1.7 million in Q2 2026.
- On a quarterly basis, Research & Development rose 12.67% year-over-year to $1.7 million in Q2 2026; TTM through Jun 2026 was $6.7 million, a 10.9% increase from a year earlier, with the FY2025 full-year figure at $6.0 million, down 10.2% from the prior year.
- Research & Development was $1.7 million for Q2 2026 at Talphera, up from $1.6 million in the prior quarter.
- The five-year high for Research & Development was $2.1 million in Q3 2024, with the low at $612000.0 in Q4 2022.
- Average Research & Development over 5 years is $1.4 million, with a median of $1.5 million recorded in 2025.
- The sharpest annual moves came in 2022 and 2023: Research & Development slumped 43.57% in 2022, then soared 189.05% in 2023.
- Over 5 years, Research & Development stood at $612000.0 in 2022, then jumped by 189.05% to $1.8 million in 2023, then declined by 25.21% to $1.3 million in 2024, then gained by 17.99% to $1.6 million in 2025, then grew by 8.26% to $1.7 million in 2026.
- The last three Research & Development figures came in at $1.7 million (Q2 2026), $1.6 million (Q1 2026), and $1.6 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 202.02 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | 1.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.69 Mn |
| Mar 31, 2026 | 1.65 Mn |
| Dec 31, 2025 | 1.56 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 1.32 Mn |
| Sep 30, 2024 | 2.05 Mn |
| Jun 30, 2024 | 1.91 Mn |
| Mar 31, 2024 | 1.43 Mn |
| Dec 31, 2023 | 1.77 Mn |
| Sep 30, 2023 | 1.18 Mn |
| Jun 30, 2023 | 1.55 Mn |
| Dec 31, 2022 | 612,000.00 |
| Sep 30, 2022 | 799,000.00 |
| Jun 30, 2022 | 1.09 Mn |
| Mar 31, 2022 | 1.32 Mn |
| Dec 31, 2021 | 986,000.00 |
| Sep 30, 2021 | 1.42 Mn |
| Jun 30, 2021 | 724,000.00 |